Program Book

Recommendations

Info

Methods. Six cycles of carboplatin 560 mg/m2 on day 1, etoposide 150 mg/m2 on days 1 and 2, and vincristine 1.5 mg/m2 on day 1 were prescribed. Patients less than 36 months of age were dosed on a per kilogram basis (conversion: 30 kg = 1 m2). Toxicity was graded according to the National Cancer Institute Common Toxicity and Adverse Event Criteria, Version 3.0. Results. Five hundred and twenty-one cycles were administered to 93 patients. The median age was 28 months (range, 2-77). Three patients were under 6 months of age at initiation of chemotherapy. Grade 3-4 myelosuppression (anemia or thrombocytopenia or neutropenia) was noted in 3% of cycles. Fever and neutropenia occurred in 2 % of cycles. All other Grade 3 and higher toxicities were seen in less than 1% of cycles administered. No patient had documented hearing loss and no patient developed a second malignancy. There were no treatment related deaths. Conclusions. Standard dose CEV is associated with a very low rate of toxicity. Pediatric ophthalmologists and oncologists should not hesitate to recommend this life preserving treatment. Financial disclosure. None 1615 RB10 CONSERVATIVE TREATMENT OF INTRAOCULAR RETINOBLASTOMA: A PROSPECTIVE PHASE II RAN- DOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY LOCAL TREATMENT Livia Lumbroso-Le Rouic1, Isabelle Aerts2, David Hajaje3, Christine Lévy- Gabriel1, Alexia Savignoni3, Nathalie Algret3, François Doz2, Laurence Desjardins1 (livia.lumbroso@curie.net) 1. Department of ocular oncology, Institut Curie, Paris France 2. Department of oncologic pediatry, Institut Curie, Paris France 3. Department of Biostatistics, Institut Curie, Paris France Purpose. Intraocular retinoblastoma treatments often associate chemotherapy and focal treatments. The protocols vary and may combine two or three drugs, and different number of cycles associated to the local adjuvant treatments. A first prospective protocol of conservative treatments in our institution showed the efficacy of the use of two courses of chemoreduction with etoposide and carboplatin, followed by chemothermotherapy using carboplatin as a single agent. In order to decrease the possible long term toxicity of chemotherapy due to etoposide a prospective randomized chemoreduction protocol was conducted using vincristine and carboplatin vs. etoposide carboplatin Methods. The study was proposed when intial tumor characteristics did not allow front-line local treatments. The phase II randomized study of reduction chemotherapy used treatments vincristin carboplatin or etoposide carboplatin, and followed by local treatment including chemothermotherapy with carboplatin only. Primary endpoint was the need for secondary enucleation or EBRT not exceeding 40% at two years. Results. 55 children, 65 eyes were included in the study (May 2004- August 2009). 32 eyes (27 children) were treated conservatively in the arm etoposidecarboplatin and 33 (28 children) eyes in the arm vincristin carboplatin. At two years after treatment 23/33 (69.7%) eyes were treated and salvaged without EBRT or enucleation in the arm vincristin-carboplatin and 26/32 (81.2%) in the arm etoposide and carboplatin. Conclusions. Neoadjuvant chemotherapy by two cycles of vincristine and carboplatin followed by chemothermotherapy (laser diode hyperthermia combined to carboplatine as single drug) does not seem to offer an optimal local control. Financial disclosure. None RETINOBLASTOMA Abstracts 38 24 RB11 OUTCOMES OF 105 EYES WITH INTRAOCULAR RETIN- OBLASTOMA TREATED WITH SYSTEMIC CHEMO- THERAPY AND/OR LOCAL THERAPY AS FIRST TREAT- MENT Luiz F. Teixeira1,2, Carla R. Donato Macedo2, Virginia L. L Torres1,2, Camila Hiromi Hashimoto2, Juliana dos Santos Soares2, Clelia M. Erwenne1,2 (luizfteixeira@hotmail.com) 1. Department of ophthalmology/ Unifesp- Federal University of Sao Paulo 2. Pediatric Oncology Institute/GRAACC/Unifesp Purpose. To evaluate the outcome of 105 eyes with intraocular retinoblastoma treated with conservative treatment. Methods. Retrospective review of 85 consecutive patients with intraocular retinoblastoma (34 unilateral cases and 51 bilateral cases). Results. A total of 105 eyes, 9 group A eyes (9%), 22 group B eyes (21%), 17 group C eyes (16%), 43 group D eyes (41%) and 14 group E eyes (13%) were treated. Systemic chemotherapy associated with local therapy was performed as first treatment in 97 eyes (92%). Periocular carboplatin injection (20mg/2ml) was used in 13 group D eyes (30%) and in 7 group E eyes (50%) associated with systemic chemotherapy. Disease progression was observed in 57% (n=60 eyes) during the first treatment period (B-32%, C-35%, D-86% and E-86%). Enucleation was performed in 28 eyes (27%). Recurrence appeared in 18 eyes from 77 eyes initially saved, after a mean follow up of 7 months (range 4-12 months). Seven eyes were enucleated. Considering all forms of conservative treatments and excluding EBRT, the final eye salvage rate was respectively: 100%/100% for group A, 95%/95% for group B, 88%/82% for group C, 49%/40% for group D, 54%/54% for group D with periocular carboplatin and 28%/14% for group E. A total of 70 eyes (67%) were saved. Conclusions. Conservative treatment for intraocular retinoblastoma using systemic chemotherapy associated with local therapy is very efficient for initial disease. Most of the enucleations (80%) were indicated during the first treatment period. Recurrence appear most in the first year of follow up. Financial disclosure. None 1546 RB12 BRACHYTHERAPY IN THE TREATMENT OF RETINO- BLASTOMA. EXPERIENCE IN A SPANISH POPULA- TION Mónica Asencio-Duran, José Abelairas, José-María Peralta, José-Maria Fernández-Guardiola, Ernesto Sánchez-jacob (masedur@hotmail.com) Hopsital La Paz, Madrid, Spain Purpose. To study the efficacy of brachytherapy in retinoblastoma as a consolidation treatment in structural and functional terms. Methods. Descriptive, retrospective and longitudinal study in a series of 86 treatments in 80 retinoblastomas belonging to 67 eyes in a Spanish reference Hospital. Results. There were 23 men/34 women, with a medium age at diagnosis
of 10.4 months. 53 % were unilateral, with involvement of the RE in 51 %, and the most frequent symptom was leucocoria (49 %), followed by strabismus (35 %). The most frequent Reese-Ellsworth groups were Va (17 cases), IIa (15 cases) and IIb (12 cases). All patients were treated with VEC, with a 23 % reduction in tumour volume. 76 % of the eyes received only 1 treatment, 21 % 2, and 1,5 % received 3 and 4 treatments. 93 % were carried out once in a tumor, whereas in 6 it was necessary to repeat the treatment. The most used plaque was Ruthenium in 95 %. The dose was 4000 cGy to the apex in all cases. With the combined regimen of QR and brachytherapy we have obtained a survival rate of 100 %, and a 0% rate of metastasis, trilateral retinoblastoma and second neoplasia with an average follow-up of 2.6 years. The conservation rate of the globe was high in the group treated with brachytherapy (66 % opposite to 34 % of non-treated). 95,5 % of the treated eyes had good tumour response, whereas only 3 were enucleated due to bad response to the brachytherapy (4,5 %). The complications associated were the appearance of retinopathy in 61 %, optical neuropathy in 7,6 % and cataracts in 6 % of the cases. Conclusions. A consolidation treatment is necessary in spite of a good initial response to chemotherapy. Brachytherapy has demonstrated to be a “curative” treatment in a wide spectrum of disease due to the great availability of plaques and isotopes. In addition, the treatments are easy to realize, short and repeatable, being able to have a certain preventive effect of enucleation, since it supports more eyes and during more time than chemotherapy alone. Nevertheless, it is not capable of preventing the appearance of new tumors and massive seeding, main reasons for enucleation, and the complication rate is not negligible, being the main cause of vision loss. Financial disclosure. None 2130 RB13 THE RADIOTHERAPY IN COMPLEX TREATMENT OF ADVANCED RETINOBLASTOMA IN CHILDREN Tatiana Ushakova1, Igor Glekov2, Olga Gopovtzova3, Igor Dolgopolov4, Alentina Pavlovskaya5, Irina Matveeva6, Vladimir Polyakov3, Geordge Mentkevich2 (ushtat07@mail.ru) 1. Institute of Pediatric Oncology and Haematology N.N. Blokhin Cancer Research Center Rams Moscow, Tumors Head and Neck; 2. Institute of Pediatric Oncology and Haematology, Radiology; 3. Institute of Pediatric Oncology and Haematology, Tumors Head and Neck; 4. Institute of Pediatric Oncology and Haematology, BMT; 5. N.N. Blokhin Cancer Research Center Rams, Pathology Anatomy; 6. N.N. Blokhin Cancer Research Center Rams, Cytology, Moscow, Russian federation Purpose. To determine the place of external beam radiotherapy (EBR) in treatment of children with advanced retinoblastoma (Rb). Methods. From 2001 to 2008, 65 of patients with Rb were treated in risk-adapted protocol at our institute. For group I there were 43 patients with unilateral Rb had undergone primary enucleation. 17 of 43 patients had insufficiency or minimum tumor invasion choroid and prelaminar invasion of the optic nerve (Ia – group). The adjuvant therapy was not administrated for patients of this group. 18 of 43 patients had invasion into the anterior chamber massive tumor invasion choroid, intra- and retrolaminar invasion of the optic nerve (Ib-group). The adjuvant CT included 4 courses of combination of CY, VP-16, Carbo. In addition to the above, only 4 from 11 patients who had retrolaminar invasion of the optic nerve received orbital EBR at a dose of 50 Grey. 8 of 43 had tumor invasion of optic nerve transection and extrascleral extention (Ic-group) and 7 of 8 received postenucleation EBR (50 Grey), 4 courses of the same RETINOBLASTOMA Abstracts 39 CT and high-dose CT included BU and MELPH followed by autologous peripheral blood stem cells transplantation (APBSCT). For group II there were 8 patients (unilateral Rb n=6) had initial extraocular disease and 5 of them were treated with neoadjuvant CT and after they underwent operation followed by CT, EBR and high-dose CT also followed by APBSCT. Last III group there were 21 patients had undergone organsaving treatment of advanced intraocular Rb and 10 of them received combined CT (CY, VP-16, carbo) and EBR at a dose of 46 Gy (IIIa-group). Results. The patients from group Ia had disease free survival (DFS) of full 100% with a median period of follow-up of 45 m. The patients from group Ib had DFS of 89% with a median period of follow-up of 78 m. The patients from groups Ic and II had DFS of 64% with a median period of follow-up of 56 mos. 4 of 16 patients in groups Ic and II were excluded from study. The patients from group IIIa had DFS of 80% with a median period of follow-up of 48 m. Conclusions. Revision of the indications to after initial enucleation in depends of histopathologic findings was done. EBR is one of effective methods for preventive of relapses in extraocular Rb after CT and operation. Combined CT and EBR generally employed in organ-saving treatment of advanced intraocular Rb. Financial disclosure. None 1909 Rb14 RESULTS OF PATIENTS WITH UNILATERAL RETINO- BLASTOMA TREATED WITH INITIAL ENUCLEATION: A SINGLE INSTITUTION IN BRAZIL Carla R. Donato Macedo1, Luiz F. Teixeira1,2, Camila H. Hashimoro1, Virginia L. L Torres 1,2, Juliana dos Santos Soares, Maria T. Seixas1,3, Maria C. Martins2, Clelia M. Erwenne1,2 (carladonatomacedo@uol.com.br) 1. Pediatric Oncology Institute/GRAACC/Unifesp 2. Ophthalmology Department/Unifesp 3. Pathology Department /Unifesp Purpose. Evaluation of patients with unilateral retinoblastoma treated with initial enucleation. Methods. A retrospective analysis of patients with unilateral retinoblastoma that underwent enucleation as initial therapy from 2001 to 2011 in a single institution in Brazil. Enucleation was indicated as primary treatment for patients with massive unilateral disease. The presence of pathology high risk features, such as massive choroidal invasion, any degree of concomitant choroid and optic nerve involvement, tumor involving the optic nerve posterior to the lamina cribosa, was indication of six cycles of adjuvant chemotherapy. If the surgical margin was compromised orbit radiotherapy was indicated. Results. In our data 123 patients had unilateral retinoblastoma (67,2 % of retinoblastoma patients). Of these, 80 patients underwent enucleation as initial therapy. Enucleation as single therapy was performed in 43 patients, 37 patients received systemic chemotherapy as adjuvant treatment and one patient was treated with external beam radiotherapy with 45Gy. Systemic chemotherapy with carboplatin and vincristine was given to 25 patients and carboplatin and etoposide to 12 patients. All the patients are alive with a median follow up of 79 months , with no recurrence or death. Conclusions. For patients with unilateral massive disease, enucleation remains the standard of care. Adjuvant chemotherapy is beneficial for selected group of patients with higher risk of extraocular dissemination. Ideally, therapy should be structured to achieve maximal response with minimal toxicity. In our data, there were no difference in the treatment with carboplatin and vincristine or etoposide, but further prospective studies must be done. Financial disclosure. None
Page 1 and 2: XV th NH City Hotel and Tower Boliv
Page 3 and 4: List of Congress Meetings of the In
Page 5: Table of Contents Welcome address K
Page 8 and 9: Keynote Lectures Lymphoma of the oc
Page 10 and 11: The venue for the Biannual Meeting
Page 12 and 13: Buenos Aires Downtown MAP 12 Venue
Page 15 and 16: MORNING 8.30-10.10 Papers (Moderato
Page 17 and 18: 50 RES 26 USING THE GLYCOLYTIC INHI
Page 19 and 20: 2226 RES 4 NOTCH SIGNALING PROMOTES
Page 21 and 22: a reduction in the number of living
Page 23 and 24: array further detected copy number
Page 25 and 26: 615 RES 21 TRB2 AND SKP2 IN THE RET
Page 27: following treatment with 2-fluorode
Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
Page 32 and 33: Posters Retinoblastoma 2006 RBp100
Page 34 and 35: 120 RBp135 MANAGEMENT OF AN ECTOPIC
Page 36 and 37: After treatment, 10 patients lived
Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
Page 42 and 43: 4. Fluoroscopy for cannula placemen
Page 44 and 45: Methods. A retrospective chart revi
Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
Page 50 and 51: months. Mean delay between beginnin
Page 52 and 53: not associated with severity of RB.
Page 54 and 55: Conclusions. During a ten-year peri
Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
Page 58 and 59: (follow-up 5 years). Two years afte
Page 61 and 62: 8.30-9.00 Poster presentations ECOp
Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
Page 65 and 66: Morning 8.30-9.00 Poster presentati
Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
Page 69 and 70: Purpose. Ocular surface squamous ne
Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
Page 73 and 74: of the tissues most commonly affect
Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
Page 77 and 78: Ocular Oncology Service, St Barthol
Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
Page 85 and 86: patients. The isolated involvement
Page 87 and 88: exudative fluid from the hemangioma
Page 89:
maximum of 7 rituximab injections.
Page 92 and 93:
153 UM14 PHENO-GENOTYPIC IDENTIFICA
Page 94 and 95:
8.30-9.00 Poster presentations UMp1
Page 96 and 97:
2253 UM1 PRELIMINARY STUDY OF VASCU
Page 98 and 99:
Purpose. To determine the presence
Page 100 and 101:
gene expression profile of melanocy
Page 102 and 103:
the rarity of UM, timely completion
Page 104 and 105:
C. Metz, T. Gkika, W. Sauerwein, N.
Page 106 and 107:
Patients in the triamcinolone group
Page 108 and 109:
1350 Ump101 INDUCED EXPRESSION OF P
Page 110 and 111:
Purpose. To report the Results of R
Page 112 and 113:
1547 Ump113 LONG-TERM OBSERVATIONS
Page 114 and 115:
2038 Ump119 VALUE OF DOPPLER ANALYS
Page 116:
Methods. A total of 4070 patients w
Page 119:
First authors Naseripour, Masood No
show all

Program Book

Create successful ePaper yourself

Delete template?

Save as template?